Ensayos clínicos

8.676 ensayos encontrados

Activo, no reclutaFase 2ClinicalTrials.gov

A Randomized, Double-Blind, Placebo-Controlled Multicenter Study to Evaluate the Efficacy and Safety of CAL02 Administered Intravenously in Addition to Standard of Care in Subjects With Severe Community-Acquired Bacterial Pneumonia (SCABP)

INTERVENTIONALInicio: 22 de jul de 2023ID: NCT05776004

TerminadoFase 3ClinicalTrials.gov

A Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Assess the Efficacy, Safety, and Tolerability of Dexpramipexole Administered Orally for 52 Weeks in Participants With Severe Eosinophilic Asthma

INTERVENTIONALInicio: 27 de mar de 2023ID: NCT05813288

CompletadoFase 3ClinicalTrials.gov

A Phase III, 52 Week, Randomized, Double-blind, 3-arm Parallel Group Study, Comparing the Efficacy, Safety and Tolerability of the Fixed Dose Triple Combination FF/UMEC/VI With the Fixed Dose Dual Combinations of FF/VI and UMEC/VI, All Administered Once-daily in the Morning Via a Dry Powder Inhaler in Subjects With Chronic Obstructive Pulmonary Disease

INTERVENTIONALInicio: 30 de jun de 2014ID: NCT02164513

CompletadoFase 3ClinicalTrials.gov

Study MEA117113: Mepolizumab vs. Placebo as Add-on Treatment for Frequently Exacerbating COPD Patients Characterized by Eosinophil Level

INTERVENTIONALInicio: 24 de abr de 2014ID: NCT02105961

TerminadoFase 3ClinicalTrials.gov

An Open-label Extension Study of the Long-term Safety, Tolerability and Efficacy of Ambrisentan in Subjects With Inoperable Chronic Thromboembolic Pulmonary Hypertension (CTEPH)

INTERVENTIONALInicio: 23 de ene de 2014ID: NCT01894022

CompletadoFase 2ClinicalTrials.gov

A Randomized Phase 2 Study of Ixabepilone Plus Carboplatin and Paclitaxel Plus Carboplatin in Patients With Advanced Non-small Cell Lung Cancer

INTERVENTIONALInicio: 1 de dic de 2008ID: NCT00723957

TerminadoFase 3ClinicalTrials.gov

A Randomized, Double-blind, Placebo-controlled, Phase III Study Evaluating the Efficacy and Safety of Canakinumab in Combination With Docetaxel Versus Placebo in Combination With Docetaxel in Adult Subjects With Non-small Cell Lung Cancer (NSCLC) Previously Treated With PD-(L)1 Inhibitors and Platinum-based Chemotherapy (CANOPY 2)

INTERVENTIONALInicio: 23 de ene de 2019ID: NCT03626545

CompletadoFase 3ClinicalTrials.gov

DB2116960: A Randomized, Double-Dummy, Parallel Group, Multicenter Trial Comparing the Efficacy and Safety of UMEC/VI (a Fixed Combination of Umeclidinium and Vilanterol) With Tiotropium In Subjects With COPD Who Continue To Have Symptoms on Tiotropium

INTERVENTIONALInicio: 15 de sept de 2014ID: NCT01899742

ReclutandoClinicalTrials.gov

Institutional Registries of Rare Diseases at Hospital Italiano de Buenos Aires (HIBA)

OBSERVATIONALInicio: 1 de jul de 2024ID: NCT06573723

Activo, no reclutaFase 2ClinicalTrials.gov

A Phase 2, Open-label, Randomized, Multicenter Study of Tarlatamab Dosing Regimens in Subjects With Small Cell Lung Cancer (SCLC) (DeLLphi-309)

INTERVENTIONALInicio: 26 de feb de 2025ID: NCT06745323

CompletadoClinicalTrials.gov

Vagus Nerve Stimulation ARDS Prevention Trial for COVID-19 Hospitalized Patients

INTERVENTIONALInicio: 27 de jun de 2020ID: NCT04379037

CompletadoFase 2ClinicalTrials.gov

A Multi-center, Randomized, Double-blind, Placebo and Active-controlled Study With Exploratory Dose-ranging to Investigate the Efficacy and Safety of 16 Weeks Treatment With Subcutaneous (s.c.) QGE031 in Asthma Patients Not Adequately Controlled With High-dose Inhaled Corticosteroids and Long Acting β2-agonists

INTERVENTIONALInicio: 1 de dic de 2012ID: NCT01716754

CompletadoFase 3ClinicalTrials.gov

A Phase III, Randomized, Double-blind, Active Controlled, Parallel Group Study, Comparing the Efficacy, Safety and Tolerability of the Fixed Dose Combination FF/UMEC/VI With the Fixed Dose Dual Combination of FF/VI, Administered Once-daily Via a Dry Powder Inhaler in Subjects With Inadequately Controlled Asthma

INTERVENTIONALInicio: 13 de oct de 2016ID: NCT02924688

CompletadoFase 3ClinicalTrials.gov

A 12-Month, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Reslizumab (3.0 mg/kg) in the Reduction of Clinical Asthma Exacerbations in Patients (12-75 Years of Age) With Eosinophilic Asthma

INTERVENTIONALInicio: 1 de mar de 2011ID: NCT01285323

CompletadoFase 3ClinicalTrials.gov

A Multi-center, Randomized, Double-blind, Placebo-controlled, Phase 3 Study of Single-agent Tarceva® (Erlotinib) Following Complete Tumor Resection With or Without Adjuvant Chemotherapy in Patients With Stage IB-IIIA Non-small Cell Lung Carcinoma Who Have EGFR-positive Tumors

INTERVENTIONALInicio: 1 de sept de 2006ID: NCT00373425

ReclutandoFase 3ClinicalTrials.gov

IZABRIGHT-Lung01: A Randomized, Open-label, Phase 2/3 Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-based Chemotherapy in Patients With EGFR-mutated Non-small Cell Lung Cancer and Disease Progression on EGFR Tyrosine Kinase Inhibitor Therapy

INTERVENTIONALInicio: 5 de nov de 2025ID: NCT07100080

CompletadoFase 2ClinicalTrials.gov

A Randomized, Double-blind, Placebo-controlled, Parallel-group, Proof-of-Concept (PoC) Study to Assess the Efficacy, Safety and Tolerability of Itepekimab, in Participants With Non-cystic Fibrosis Bronchiectasis

INTERVENTIONALInicio: 20 de feb de 2024ID: NCT06280391

ReclutandoFase 3ClinicalTrials.gov

A Phase 3, Double-Blind, Randomized, Placebo-Controlled Study of Levosimendan in Pulmonary Hypertension Patients With Heart Failure With Preserved Left Ventricular Ejection Fraction

INTERVENTIONALInicio: 1 de dic de 2025ID: NCT07288398

CompletadoFase 2ClinicalTrials.gov

A Multicenter, Single-Treatment Study to Assess the Safety and Tolerability of Lyophilized Lucinactant in Adults With COVID-19 Associated Acute Lung Injury

INTERVENTIONALInicio: 5 de ene de 2021ID: NCT04389671

CompletadoClinicalTrials.gov

End-Inspiratory Pause Enhances Ventilation Efficiency Without Affecting autoPEEP in COPD Patients During Controlled Ventilation

INTERVENTIONALInicio: 1 de oct de 2024ID: NCT07207967